ArticleJournal of neuro-oncology2026
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with metastatic triple-negative breast cancer (mTNBC) and brain metastases (BM) have poor prognosis and limited treatment options. In the ASCENT trial, sacituzumab govitecan (SG) showed modest progression-free survival (PFS) benefit but no overall survival (OS) advantage in a subgroup with stable BM. To address the limited evidence, we evaluated SGs effectiveness and safety in a real-world cohort. MATERIALS AND
methodsThis retrospective multicenter study included patients with mTNBC and radiologically confirmed BM treated with ≥2 L SG at 13 centers in the Czech Republic, Poland and Slovakia. Clinical data included baseline features, BM characteristics, CNS-directed therapies, treatment response and safety. PFS and OS were assessed using Kaplan-Meier estimates; univariable Cox models evaluated the impact of BM burden on survival.
results29 women were included. Median number and size of BM were 3 and 16.5 mm, respectively. Prior neurosurgery was performed in 4 patients (14.3%) and radiotherapy in 28 (89.3%). Most had received ≥2 prior systemic therapies. After a median follow-up of 6.05 months, median OS was 8.9 months and PFS 3.09 months. Overall response rate was 30.8%, with CNS progression in 23.1%. Neither BM number nor size significantly affected survival. SG required dose delays in 51.7% and reductions in 37.9%; 7.7% discontinued due to toxicity. No unexpected safety signals were observed.
conclusionsSG showed activity and manageable safety in real-world mTNBC with BM, with PFS and OS comparable or superior to the ASCENT BM subgroup. Outcomes were unaffected by BM burden, indicating SG efficacy irrespective of its extent.
Indexed as
Identifiers
41533274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.